Get started
Author

L. Yen

Acute diverticulitis: demographic, clinical and laboratory features associated with computed tomography findings in 741 patients
2012 · G. F. Longstreth, R. L. Iyer, et al. · Alimentary Pharmacology & Therapeutics · 46
The impact of MMX mesalazine on disease‐specific health‐related quality of life in ulcerative colitis patients
2012 · D. Solomon, A. Yarlas, et al. · Alimentary Pharmacology & Therapeutics · 15
Development Of Patient-Reported Outcomes (Pro) And Observer-Reported Outcomes (Obsro) Measures For Pediatric Ulcerative Colitis: Concept Elicitation Findings
2013 · L. Yen, E. Flood, et al. · Value in Health · 2
PGI28 Disease-Specific Health-related Quality of Life in Patients with Quiescent Ulcerative Colitis: Effects of one Year Maintenance Treatment with MMX Mesalamine
2011 · D. Solomon, A. Yarlas, et al. · Value in Health · 2
PGI23 Economic Impact of Medication Adherence and Persistence in the Treatment of Ulcerative Colitis in Canada: Analyses with the Ramq Database
2011 · J. Lachaine, L. Yen, et al. · Value in Health · 2
PDF
PGI29 Predictors of Nonpersistence and Nonadherence with Oral 5-Aminosalicylic Acid Therapy in Patients with Ulcerative Colitis
2012 · L. Yen, J. Wu, et al. · Value in Health · 1
Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs
2009 · M Debanjali, P Hodgkins, et al. · Inflammatory Bowel Diseases · 1
P309 Adherence to 5-aminosalicylic acid therapies in ulcerative colitis: a United Kingdom budget impact analysis
2013 · A. Szende, D. Neves, et al. · Journal of Crohn s and Colitis
P410 Physician-initiated treatment patterns of ulcerative colitis patients in the United Kingdom: a review of chart-abstracted data
2013 · L. Yen, B.J. Katic · Journal of Crohn s and Colitis
PGI6 Adherence to 5-Aminosalicylic Acid (5-ASA) Therapy for Ulcerative Colitis (UC): Impact on Health Care Costs
2012 · L. Yen, T.K. Knight, et al. · Value in Health
PDF
PGI10 Factors Associated With Treatment Adherence and Persistence in Canadian Patients With Ulcerative Colitis (Uc): Analysis of Prescription Claims From the Ramq Database
2012 · J. Lachaine, L. Yen, et al. · Value in Health
PGI7 Adherence to 5-Aminosalicylic Acid (5-ASA) Therapies in Ulcerative Colitis (UC): A UK Budget Impact Analysis
2012 · A. Szende, D. Neves, et al. · Value in Health
PGI9 Analysis of Adherence With Oral 5-Aminosalicylic Acid (5-ASA) Therapy in Patients with Ulcerative Colitis (UC) in a Uk Pharmacy Database
2012 · M. Hankins, M. Nedham, et al. · Value in Health
PHP36 Comparing Oral 5-Aminosalicylic Acid Treatment Persistence and Adherence in Patients with Ulcerative Colitis in the United States
2012 · L. Yen, J. Wu, et al. · Value in Health
PDF
PHS98 Clinical Characteristics, Treatment Patterns, and Resource Utilization in a Real-World European Population With Diverticulitis
2012 · K.L. Davis, D. Mitra, et al. · Value in Health
PDF
PGI40 Physician-Initiated Treatment Patterns of Ulcerative Colitis (UC) Patients in the UK: a Review of Chart-Abstracted Data
2012 · L. Yen, B.J. Katic · Value in Health
PGI14 Characteristics of Diverticulitis-Related Emergency Department Visits in the United States
2012 · S.D. Candrilli, K.L. Davis, et al. · Value in Health
PDF
PTU-097 Medical resource utilisation and costs in patients with ulcerative colitis in the UK: a chart review analysis: Abstract PTU-097 Table 1
2012 · K Bodger, L Yen, et al. · Gut
PDF
PGI20 Pre- to Post-Diagnosis Increase in Utilization and Costs of Chronic-Use Medications and Other Medical Resources in Managed Care Enrollees with Diverticulitis
2012 · K.L. Davis, L. Yen, et al. · Value in Health
PGI26 Resource Utilization and Costs Associated with Diverticulitis Inpatient Admissions: An Analysis of the Economic Burden of Diverticulitis
2012 · B. Spiegel, P. Poysophon, et al. · Value in Health
PGI3 Validation of Algorithms to Identify Diverticulitis Through Electronic Medical Records in Kaiser Permanente Southern California (KPSC)
2012 · A.A. Kawatkar, L.H. Chu, et al. · Value in Health
PGI16 The Direct Economic Burden of Diverticulitis Recurrence among Managed Care Enrollees
2012 · L. Yen, K.L. Davis, et al. · Value in Health
PGI31 The Maintenance of Work-related Productivity During One Year of MMX Mesalamine Treatment for Patients with Quiescent Ulcerative Colitis
2011 · L. Yen, A. Yarlas, et al. · Value in Health
Pgi22 Concordance Among Multiple Health Outcomes Measures in Responsiveness to Multi-matrix Mesalamine Maintenance Treatment for Patients With Quiescent Ulcerative Colitis
2011 · L. Yen, A. Yarlas, et al. · Value in Health
Pgi21 Health-related Quality of Life in Patients With Mild-to-moderate Ulcerative Colitis Before and After 8 Weeks' Treatment With Multi-matrix Mesalamine: Comparison With 2009 General Population Norms in the United States
2011 · A. Yarlas, L. Yen, et al. · Value in Health
Works count: 28
Citation count: 69
H-index: 2
I10-index: 2
Year
Topic
Type